In a report released today, Robyn Karnauskas from Citigroup maintained a Buy rating on Vertex Pharmaceuticals (VRTX), with a price target of $205. The company’s shares opened today at $165.90.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of 4.5% and a 48.3% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Biogen Inc, and Amgen Inc.
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $204.54.
See today’s analyst top recommended stocks >>
The company has a one-year high of $194.92 and a one-year low of $144.07. Currently, Vertex Pharmaceuticals has an average volume of 1.46M.
Based on the recent corporate insider activity of 120 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRTX in relation to earlier this year. Most recently, in December 2018, Bruce Sachs, a Director at VRTX bought 10,000 shares for a total of $342,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Read More on VRTX:
